Get the Stockscreener App
41.99
0.11%
0.045
After Hours:
38.27
-3.725
-8.87%
Moderna Inc stock is traded at $41.99, with a volume of 9.64M.
It is up +0.11% in the last 24 hours and up +22.43% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$41.95
Open:
$42.87
24h Volume:
9.64M
Relative Volume:
0.84
Market Cap:
$16.41B
Revenue:
$3.14B
Net Income/Loss:
$-3.36B
P/E Ratio:
-4.8104
EPS:
-8.73
Net Cash Flow:
$-4.03B
1W Performance:
-0.49%
1M Performance:
+22.43%
6M Performance:
+60.78%
1Y Performance:
+31.77%
1-Day Range:
$41.68
$45.50
1-Week Range:
$39.50
$45.50
52-Week Range:
$22.28
$55.20
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
41.99 | 16.39B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.48 | 119.47B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.91 | 82.49B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.16 | 51.25B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.98 | 42.28B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
353.43 | 38.60B | 4.98B | 69.60M | 525.67M | 0.5198 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Equal Weight |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-12-25 | Initiated | Jefferies | Hold |
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
F.D.A. Refuses to Review Moderna Flu Vaccine - The New York Times
Moderna says US refusing to review mRNA-based flu shot | National | dailygazette.com - The Daily Gazette
Moderna Says US Refusing To Review MRNA-based Flu Shot - Barron's
FDA refuses to review Moderna’s flu vaccine in latest setback - GMToday.com
Moderna Cites Changing Advice As US FDA Refuses To File Flu Vaccine BLA - Citeline News & Insights
Why Did Moderna Stock Tumble Nearly 10% After Hours Today? - Stocktwits
FDA Refuses To Review Moderna's Flu Vaccine Application - Health and Me
FDA Tosses Flu Vaccine Application Back To Moderna With RTF Letter - Citeline News & Insights
FDA Refuses to Consider Approving Use of Moderna’s New Flu Vaccine - The Wall Street Journal
Moderna (MRNA) Faces FDA Setback with Influenza Vaccine Applicat - GuruFocus
Moderna (MRNA) Shares Decline After FDA Rejects Flu Vaccine Appl - GuruFocus
FDA refuses to review Moderna's flu vaccine application - The Business Journals
Moderna shares slide 7% after FDA refuses to review flu vaccine - Investing.com UK
FDA Refuses to Review Moderna’s Flu Vaccine in Latest Setback - Bloomberg.com
Moderna says FDA refuses its application for new mRNA flu vaccine - WRAL
FDA refuses to review Moderna’s influenza vaccine application By Investing.com - Investing.com India
Moderna says US FDA refuses to review its influenza vaccine - TradingView
FDA refuses to review Moderna's influenza vaccine application - Reuters
Moderna Receives Refusal-to-File Letter from the U.S. Food and Drug Administration for Its Investigational Seasonal Influenza Vaccine, mRNA-1010 - ACCESS Newswire
FDA refuses to review Moderna’s application for mRNA flu vaccine, company says - AOL.com
Fda refuses to consider approving use of Moderna's new flu vaccineWSJ - marketscreener.com
Moderna says FDA refuses to review its application for experimental flu shot - CNBC
FDA declines to review Moderna's mRNA flu shot - NBC News
Moderna signs 5-year vaccine deal with Mexican government - NBC Boston
Moderna to Enter into Long-Term Strategic Agreement with the Government of Mexico - USA Today
1 Reason I'd Buy Vertex Pharmaceuticals Stock and Never Sell - The Motley Fool
Moderna inks five-year Mexico deal as it pushes geographic expansion to hit breakeven - The Business Journals
Moderna to supply respiratory vaccines to Mexico (MRNA:NASDAQ) - Seeking Alpha
Moderna, Mexico Partner To Boost Local Vaccine Production - Benzinga
Jim Cramer on Moderna: "One of the Hottest Stocks in the Market This Year" - Finviz
Jim Cramer on Moderna: “One of the Hottest Stocks in the Market This Year” - Yahoo Finance Singapore
Moderna signs mRNA vaccine supply and tech transfer deal with Mexico By Investing.com - Investing.com South Africa
Moderna Signs Long-Term mRNA Manufacturing Agreement With Mexican Government - marketscreener.com
United States Biotechnology Market to hit US$ 1.5 Trillion - openPR.com
Moderna signs mRNA vaccine supply and tech transfer deal with Mexico - Investing.com India
What Does the Street Think About Moderna, Inc. (MRNA)? - Insider Monkey
Moderna (MRNA) Gets a Sell from Bank of America Securities - The Globe and Mail
Should You Buy Moderna Before Feb. 13? - The Globe and Mail
Moderna (MRNA) Laps the Stock Market: Here's Why - Yahoo Finance Australia
How Investors Are Reacting To Moderna (MRNA) Denied Immunity In High-Stakes Vaccine Patent Case - Yahoo Finance
Palmetto Grain Brokerage - Palmetto Grain Brokerage
Will These 5 Drug Bigwigs Surpass Q4 Earnings Forecasts? - TradingView
Moderna to Report Q4 Earnings: Is a Beat in Store for the Stock? - Nasdaq
A Double Blow for Moderna – Seqirus Topples Two mRNA Patent Applications - Pearce IP
1 Stock to Buy, 1 Stock to Sell This Week: Cisco, Moderna - Investing.com Nigeria
Moderna Balances $5b Patent Trial Risk With Oncology Leadership Shift - Yahoo Finance
United StatesGoodwin Advises Moderna On Strategic Collaboration With Recordati To Globally Commercialize Investigational Propionic Acidemia Therapeutic (MRNA-3927) For $50 Million Upfront And Up To $110 Million In - Mondaq
Mixed Options Sentiment as Moderna (MRNA) Sees Slight Decline - GuruFocus
Moderna (MRNA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release - Finviz
Moderna faces $5 billion mRNA patent lawsuit after ‘Star Trek’ ruling - thestreet.com
Here is What to Know Beyond Why Moderna, Inc. (MRNA) is a Trending Stock - Yahoo Finance
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.36%
1.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):